U.S. market Open. Closes in 1 hour 10 minutes

PTGX | Protagonist Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for PTGX we got that it has average fundamentals where Valuation is considered to be slightly overvalued, Profitability is stunning wealthy, Growth is bad and Health is passable.

Valuation (45%)

Company Industry
P/E Ratio (TTM) 14.21 -18.09
PEG Ratio (TTM) 9.87 -5.18
P/S Ratio (TTM) 7.23 52.20
P/B Ratio (TTM) 4.56 28.91
P/FCF Ratio (TTM) 10.22 -7.12
Price to 5YR AVG Earnings Ratio -17.15 -7.20
Price to 5YR AVG FCF Ratio -28.97 -13.31

Profitability (95%)

Company Industry
ROA (TTM) 28.29% -16.66%
ROE (TTM) 34.68% 27.93%
Net Profit Margin (TTM) 52.77% -796.50%
ROIC 5YR AVG 29.81% -20.53%

Growth (50%)

4QTR AVG 3YR AVG 5YR AVG
EPS 178.18% -24.57% -4.79%
Revenue 59.69% 4,063.13% 2,462.45%
Net Income 178.86% -56.46% -26.80%
Cash Flow 217.74% -35.50% -14.34%

Health (56%)

Company Industry
Current Ratio (TTM) 10.70 5.80
Quick Ratio (TTM) 10.70 5.58
D/E Ratio (TTM) N/A 0.97
Interest Coverage (TTM) 64.94 -7.65
Piotroski F-Score 5 5
Altman Z-Score 20.77 13.09
LTL to 5YR AVG FCF N/A 0.07
Shares Outstanding Growth 5YR AVG 20.98% 40.92%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙